CJC-1295 With DAC vs Without DAC: Half-Life, Dosing, and Which One Is in Your Vial

The price is all-in and covers the medication, physician review, refill management and shipping, with no separate membership fee. Which form your pharmacy supplies is on your label.

What the choice really turns on

People searching "with DAC vs without DAC" usually expect a stronger and weaker version. That is not the difference. They act at the same receptor and do the same job. The difference is time: one is a short pulse, the other a continuous signal lasting days. The no-DAC form is the one compounded in blends: dosed daily and paired with ipamorelin, it gives one clean pulse per dose rather than a week-long elevation.

Growth-hormone-releasing hormone (GHRH) is a 44-amino-acid peptide made in the hypothalamus that tells the pituitary to release growth hormone. Its first 29 amino acids are the smallest fragment that keeps full activity at the GHRH receptor; that fragment is sermorelin. Native GHRH and sermorelin are cleared by enzymes within minutes.

CJC-1295 starts from that same 29-amino-acid fragment and changes four positions along the chain to protect it from the enzyme DPP-IV, which breaks native GHRH down. A 2005 paper in Endocrinology described the design and identified CJC-1295 as a long-lasting GHRH analogue activating the GHRH receptor in rats. Both forms below carry those four changes. Only one adds the DAC.

Neither form contains growth hormone. Both ask your own pituitary to release what it already makes, with the body's brakes (somatostatin from the hypothalamus and feedback from IGF-1 made in the liver) still in place. The broader distinction is in peptides vs HGH.

Ipamorelin is a five-amino-acid peptide that acts at a different receptor on the same pituitary cells: the growth hormone secretagogue receptor (GHS-R1a), the one ghrelin uses. A 1998 paper in the European Journal of Endocrinology described it as the first selective growth hormone secretagogue, releasing growth hormone in animal models without raising cortisol, ACTH or prolactin. A 1999 paper in Pharmaceutical Research modelled its growth hormone response in human volunteers given intravenous doses, with a half-life measured in hours.

The two classes are described as more than additive. A 1995 paper in Clinical Endocrinology reported a larger response from a GHRH plus GH-releasing-peptide combination than from either alone. Ipamorelin also reduces somatostatin at the hypothalamus, taking a brake off. One dose of both, on an empty stomach, is intended to produce a single pulse resembling the body's own nocturnal pulse.

That is the reason the compounded pairing uses the no-DAC form: a short GHRH signal alongside ipamorelin gives one clean pulse per dose, rather than a week-long elevation.

The no-DAC form. CJC-1295 / Ipamorelin is a 5 mL multi-dose vial containing CJC-1295 1.2 mg/mL and ipamorelin 2.4 mg/mL, which is 6 mg CJC-1295 and 12 mg ipamorelin per vial. Your label states what you are prescribed.

CJC-1295 also appears, with ipamorelin, in several Pepti blends:

If you want the GHRH side kept shorter still, Ipamorelin + Sermorelin at $219/mo is the equivalent pairing built on sermorelin. The comparison is in CJC-1295 vs sermorelin, and the three single agents are compared in sermorelin vs tesamorelin vs ipamorelin.

The half-life sets the schedule. A DAC-form peptide that lasts days is given infrequently. A no-DAC form that lasts about half an hour has to be given daily to produce a daily pulse.

Pepti's CJC-1295 / Ipamorelin is directed as 0.25 mL, which is 25 units on a U-100 insulin syringe, injected under the skin (subcutaneously) once daily Monday through Friday on an empty stomach. That is 20 doses per vial, about four weeks, which is why refills run every 28 days, one vial per fill. The empty-stomach instruction matters: glucose and fatty acids after a meal blunt the growth hormone pulse. Many prescribers direct it at bedtime so the induced pulse lines up with the body's own deep-sleep pulse. You do not need to calculate anything: your directions are printed on the vial, and your physician sets them after reviewing your intake. More on reading a label is in how long does a peptide vial last.

The vial ships refrigerated with ice packs, ready to use, with sterile syringes and alcohol prep pads, and stays in the fridge between doses.

Both forms are the same category. In the 2006 DAC trials, injection-site reactions and headache were the main complaints. What is reported clinically with the no-DAC pairing is injection-site redness or soreness, a brief flush after injecting, headache, and, with the growth hormone rise, water retention or tingling in the hands, which usually settle. Some people notice hunger after a dose, because ipamorelin acts at the receptor ghrelin uses.

Two things a physician considers at intake: growth hormone opposes insulin, so diabetes or impaired glucose tolerance is raised; and because the IGF-1 axis supports tissue growth, a personal history of cancer is raised. The longer exposure of the DAC form is one reason prescribers favour the short-acting form. There is no long-term safety dataset over years for either form. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. Stop and contact your physician for any reaction that is severe, spreading, or involves difficulty breathing. More in is CJC-1295 / ipamorelin safe.

CJC-1295 has no approved-drug history, so its only route into 503A compounding is the FDA's bulk substances list. It appeared in Category 2 of the interim list on the version dated 29 September 2023. On the version dated 27 September 2024 it was removed from Category 2 because the nominations were withdrawn, and the FDA referred it to its Pharmacy Compounding Advisory Committee.

On 4 December 2024 the committee, evaluating the CJC-1295 family for growth hormone deficiency, voted 0 to 13 against CJC-1295 (free base), 1 to 12 against CJC-1295 acetate, and 0 to 13 against each of the three DAC forms. That is a recommendation, not a final action. The FDA has not issued a final determination, CJC-1295 appears in no category on the interim list updated 14 May 2026, and it was not on the agenda of the July 2026 meeting. It is not banned. Ipamorelin followed a similar path, with a committee vote of 0 yes, 12 no, 1 abstain on 29 October 2024 and no final determination.

Compounded medications are not FDA approved, whichever form is used. Are peptides FDA approved explains the difference between not approved and not legal.

Anti-doping

WADA's 2026 Prohibited List names CJC-1295 among prohibited GHRH analogues and ipamorelin among growth hormone secretagogues, under S2.2.4, prohibited at all times. The list does not distinguish DAC from no-DAC. See do peptides show up on a drug test.

The DAC form has the human pharmacokinetic data: it raises growth hormone and IGF-1 in healthy adults for days, with pulses preserved. The no-DAC form, the one actually prescribed, has no human trials of its own and rests on the shared chemistry, receptor pharmacology and clinical experience. Neither form has outcome trials for sleep, recovery or body composition, and neither has long-term safety data over years. Anyone claiming the no-DAC form is "proven" for any of those is overstating it. The real difference between the two is duration, not strength or quality.

It cannot be bought legitimately without a prescription. Sites selling CJC-1295 "for research use only", with or without DAC, are not accountable for identity, purity, sterility or concentration. The prescription route:

1. Complete a free online intake covering your history, medications and goals.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A pharmacy compounds it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and dose changes.

Pepti prescribes CJC-1295 / Ipamorelin in all 50 states and DC. Step-by-step: how to get CJC-1295 / Ipamorelin prescribed online. The full reference is what is CJC-1295 / Ipamorelin.